Philip Morris International Inc.
NYSE: PM·Stamford, Connecticut·CIK 0001413329
- Price
- $196.04
- Base IV
- $165.74
Valuation snapshot
At $196.04, the price sits between our base case ($165.74) and bull case ($226.26).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $165.74
- 85% of the price · range $95.24–$226.26
- Price vs base case
- 18% above
- $196.04 against $165.74
- Base case · our researched forecast, 2026-11-13See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $95.24 to bull $226.26. Values per share.
Price against each value
- Bear case
- $95.24
- Price 106% above
- No growth
- …
- —
- Base case
- $165.74
- Price 18% above
What does Philip Morris International do?
Philip Morris International sells Marlboro cigarettes and smoke-free alternatives to adult nicotine users, including IQOS heated tobacco devices, ZYN nicotine pouches and e-vapor products.
It brought in $43.1B of sales in the 12 months to Sep 2026.
Led by Jacek Olczak, Group CEO PMI since 2026. Philip Morris International Inc. Form 10-K for fiscal year 2025 (Item 10, executive officers as of February 6, 2026)
- Industry
- Consumer staples
- Based in
- Stamford, Connecticut
- Trades on
- NYSE as PM
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 25¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 32¢ of every dollar.
- Making what it sells32¢
- Everything else it takes to operate29¢
- Interest and other costs2¢
- Tax8¢
- Other items after tax4¢
- Left as profit25¢
Who pays Philip Morris International, and for what?
Philip Morris International makes and sells tobacco and nicotine products in about 170 markets. Most of its money still comes from cigarettes, led by Marlboro. A growing share comes from smoke-free products: IQOS heated tobacco devices and sticks, ZYN nicotine pouches and VEEV vapes. It earns its money mostly through price increases and by selling more smoke-free products.
Adult smokers and nicotine users buy its products, usually through distributors, wholesalers and retailers, and in 2025 two distributors each accounted for at least 10% of its revenue.
Cigarettes (combustible tobacco)
Cigarettes sold in about 170 markets under brands such as Marlboro, Parliament, Chesterfield, L&M and local brands. They made up 607 billion of the 786 billion units shipped in 2025, and cigarette volume fell 1.5%.
Marlboro cigarette pack and cigarettes sold with an Italian health warning.Nicholas Gemini, CC BY-SA 3.0, via Wikimedia Commons Heat-not-burn (IQOS)
Devices that heat tobacco sticks such as TEREA and HEETS instead of burning them. They are the largest smoke-free product, with 155 billion sticks shipped in 2025, up 11%.
IQOS ILUMA i PRIME heated-tobacco holder and pocket charger.Image: Philip Morris International Oral nicotine (ZYN and snus)
Nicotine pouches and snus that users place under the lip, led by ZYN, which came with the 2022 purchase of Swedish Match. Volume grew 18.5% in 2025, and pouches are now sold in 56 markets.
ZYN Cool Mint nicotine-pouch can and individual pouches.Aphis Marta, CC BY-SA 4.0, via Wikimedia Commons E-vapor (VEEV)
Electronic vapes that heat a nicotine liquid. This is a small line, but its volume doubled in 2025.
VEEV inPRIME vape shown with its pod and internal components.Image: Philip Morris International Wellness (Aspeya)
An early-stage unit building oral wellness products, including some CBD products. The company expects revenue from it to be negligible in the near to medium term.
Where its work physically happens, beyond headquarters:
- Crespellano Smoke-Free Products Plant — Crespellano, Italy. PMI’s first global facility dedicated to large-scale production and export of smoke-free products is a lead manufacturing and industrialization site for the company’s strategic transition beyond cigarettes.
- Neuchâtel R&D Campus — Neuchâtel, Switzerland. The campus contains PMI’s global R&D center, prototype-development capabilities, more than 400 scientists, engineers and technicians, and a dual-product factory producing over 20 billion cigarettes and heated-tobacco units annually.
- Torbalı Factory — Torbalı, Turkey. One of PMI’s largest factories worldwide, the approximately 1,200-employee site manufactures roughly 250 product variants for Turkey and more than 20 export markets.
- Philip Morris Izhora Factory — Saint Petersburg, Russia. PMI identifies Izhora as its largest production facility worldwide, making it a major source of locally manufactured products for the Russian market.
- Karawang Factory — Karawang, Indonesia. The Karawang complex combines machine-made kretek cigarette production with dedicated smoke-free-product manufacturing for domestic demand and exports across Asia-Pacific.
How is the business doing?
Sales grew from $28.7B in 2020 to $40.6B in 2025, about 7% a year.
Running the business leaves about 39¢ of each sales dollar as operating profit, down from 41¢ in 2020.
After paying for its upkeep and new investment, it had $13.6B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
The company says it exists to replace cigarettes with smoke-free products for adults who would otherwise keep smoking, with the goal of completely ending cigarette sales.
“We are a leading international consumer goods company, actively delivering a smoke-free future and evolving our portfolio for the long term”
Who is responsible for the plan?
Jacek OlczakGroup CEO PMIHe leads Philip Morris International as Group CEO; the CEO of PMI International reports directly to him. As Group CEO he oversees the whole company, which earns its revenue by selling combustible cigarettes and smoke-free products such as heated tobacco around the world.
Frederic de WildeCEO PMI InternationalHe oversees all of PMI's geographic operating regions except the U.S., and reports directly to the Group CEO. The regions he oversees are where PMI sells its cigarettes and smoke-free products in markets outside the U.S.
- Michele CattoniChief Global Research & Development Officer
He leads PMI's global research and development organization, whose job is to advance next-generation smoke-free products. His R&D group develops the smoke-free products that PMI sells, which made up 41.5% of its total net revenues in 2025.
Roles checked November 13, 2026.
What management says it is working on now:
Grow smoke-free products
Management calls growing IQOS, ZYN and VEEV its main strategic priority. It has spent over $16 billion on these products since 2008, and they are now sold in 106 markets.
Philip Morris International 10-K for fiscal year 2025New structure: International and U.S.
From January 2026 the company runs as two business units. It now reports three segments: International Smoke-Free, International Combustibles, and U.S.
Philip Morris International 10-K for fiscal year 2025Prepare the U.S. launch of IQOS ILUMA
The company plans to spend more in the U.S. in the second half of 2026 to prepare for a future launch of its newest IQOS device, which is still waiting for U.S. regulators to approve it.
PMI Q2 2026 earnings release (Form 8-K)Pay down debt
The company plans no share buybacks in 2026 and aims to bring its debt down relative to its earnings.
PMI Q2 2026 earnings release (Form 8-K)Keep raising cigarette prices and cutting factory costs
Higher cigarette prices were a main driver of 2025 revenue growth. The company also ended cigarette production at two German factories, which added restructuring costs in 2025.
Philip Morris International 10-K for fiscal year 2025
- Adjusted diluted earnings per share, full year 2026
- $8.26 to $8.41 (up 9.5% to 11.5%)
- PMI Q2 2026 earnings release (Form 8-K)
- Smoke-free share of net revenues, by 2030
- More than two-thirds
- PMI Announces Ambition to Become a More Than Two-Thirds Majority Smoke-Free Company by 2030
What's changing right now?
Growth is slowing. In Q3 2026 it sold 5% more than a year earlier. The year before, quarters averaged 9%.
Its operating margin is wider than a year ago: 43¢ per sales dollar, against 39¢.
Since Sep 2026 the share price has risen 5%, from $186.17 to $196.04.
Recently
October 21, 2026
Quarterly international smoke-free shipment growth changed to 2.7%
PMI Q3 2026 resultsOctober 21, 2026
Quarterly reported operating margin changed to 42.5%
PMI Q3 2026 resultsOctober 21, 2026
Quarterly revenue growth year over year changed to 5.5%
PMI Q3 2026 results
Coming up
Around October 21, 2026 (estimated)
Third-quarter 2026 results
The company's own forecast for the quarter is adjusted earnings per share of $2.20 to $2.25. The report date in the timing field is an outside estimate; the company had not announced one.
PMI Q2 2026 earnings release (Form 8-K)Not disclosed
FDA decision on IQOS ILUMA
The company asked the FDA in 2023 to let it sell IQOS ILUMA in the U.S. and is preparing for a launch. No decision date has been disclosed.
Philip Morris International 10-Q for the quarter ended June 30, 2026Q3 2026
New ZYN products in the U.S.
The company planned to launch new 1.5mg and 8mg dry ZYN pouches in the third quarter of 2026, after starting to sell ZYN ULTRA in June 2026.
PMI Q2 2026 earnings release (Form 8-K)Full-year 2026 results, early 2027
New reporting segments
Since early 2026 the company reports three segments: International Smoke-Free, International Combustibles, and U.S. The first full year under this structure will show more clearly how each part is doing.
Philip Morris International 10-K for fiscal year 2025
Our own estimate moved too: the base case went from $164.84 to $165.74 a share between our last two valuations. The biggest reason: Smoke-free share of net revenues, third quarter moved from an unreported prior value to 40.0%, as reported in PMI Q3 2026 earnings release.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Strict and changing regulation
Governments keep adding tobacco rules such as flavor bans, plain packaging and bans on sales to younger generations, and some limit or ban smoke-free products. Any of these could cut demand or raise costs.
From the company's own filingsWould hit how fast sales growPhilip Morris International 10-K for fiscal year 2025
Fewer people smoking
Cigarette sales are falling in many markets because of taxes, health concerns and changing attitudes. Cigarettes still fund the company's shift to smoke-free products, so a faster decline could hurt both.
From the company's own filingsWould hit how fast sales growPhilip Morris International 10-K for fiscal year 2025
Smoke-free products could be taxed like cigarettes
Smoke-free products are usually taxed less than cigarettes, which helps their profits. Some countries have moved toward taxing them at similar rates; Germany, for example, classed TEREA sticks as cigarettes for tax purposes.
From the company's own filingsWould hit how much of each sale it keepsPhilip Morris International 10-K for fiscal year 2025
U.S. approvals and the single ZYN factory
U.S. sales depend on FDA approvals, which could be withdrawn or never granted for new products. Almost all U.S. ZYN supply comes from one factory in Kentucky.
From the company's own filingsWould hit how fast sales growPhilip Morris International 10-K for fiscal year 2025
Russia and the war in Ukraine
Russia brought in about 6% of 2025 revenue. The company could lose access to its Russian assets or have to sell them at a large loss.
From the company's own filingsWould hit how fast sales growPhilip Morris International 10-K for fiscal year 2025
Currency swings and changing tax rules
Most sales are made in foreign currencies, so a stronger dollar shrinks reported results. New global minimum tax rules and changes in where profits are earned could also raise its tax rate.
From the company's own filingsWould hit the tax it paysPhilip Morris International 10-K for fiscal year 2025
Management flagged that a favorable change in distribution terms will not recur at the same level, and Japan saw pantry-loading ahead of an excise increase
From our researchWould hit how fast sales growPMI Q3 2026 earnings release
Reported Q4 2025 margin was only about 32.6% because of charges
From our researchWould hit how much of each sale it keepsPMI FY2025 results
Is it a good business?
From 2016 to 2025 it earned between 27% and 77% on the capital invested in it, a median of 65%. Its cost of capital in the latest valuation is 7.2%; returns were above it in every one of the 10 years.
Over 10 years its operating margin ranged from 14¢ to 41¢ per sales dollar, a median of 38¢. Gross margin ran from 23¢ to 68¢.
Cost of capital 7.2%
The number of shares has held roughly steady over the past year.
It owes $40.9B more than it holds in cash, about 2.5 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $196.04. Our put its value between $95.24 and $226.26, with $165.74 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $95.24
This scenario assumes PMI's sales growth, which has run around 7% a year recently, slows to a crawl as cigarette volumes keep falling and newer products like ZYN and IQOS lose momentum, while profits per dollar of sales slip a little.
Base case, $165.74
This scenario assumes PMI keeps growing sales at roughly the 6% to 7% pace of the past few years, helped by IQOS and ZYN, before slowing gradually, and that profitability stays near today's strong levels.
Bull case, $226.26
This scenario assumes PMI's newer smokeless products like IQOS and ZYN take over a growing share of its business, pushing sales growth back toward the 9% to 10% rates seen in early 2026 and making the company even more profitable.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 18%
For Philip Morris International to be worth today's $196.04, sales would need to grow about 8.8% a year. We assume 5.4%. Over the last 5 years, sales grew 7.0% a year.
Or, if sales grow 5.4% as we assume, the price works with a profit margin of 47.4% (we assume 41.0%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 8.8% a year?
Try your own numbersWe're moderately sure of this range: it scores 61 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $165.74 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average5.4%
- Operating margin41.0%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$165.74 -15.5%


